CTOs on the Move

RayzeBio

www.rayzebio.com

 
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.rayzebio.com
  • 5505 Morehouse Drive Suite 300
    San Diego, CA USA 92121
  • Phone: 858.257.3449

Executives

Name Title Contact Details

Funding

RayzeBio raised $105M on 12/08/2020
RayzeBio raised $45M on 10/14/2020
RayzeBio raised $108M on 06/15/2021

Similar Companies

Elusys Therapeutics

Elusys Therapeutics is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA SOLUTIONS

DNA SOLUTIONS is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galenea Corp

Galenea Corp is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immuneering

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering`s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering`s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage.

Verax Biomedical Incorporated

Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.